Nathalie Picollet-D’hahan, Axel Tollance, Cristina Belda Marin, Lavinia Liguori, Christophe Marquette, Odile Filhol-Cochet, Isabelle Vilgrain, Guillaume Laffitte, Florence Rivera, Jean-Pierre Alcaraz, Jacques Thélu, Olivier Nicoud, Thibaud Moufle-Milot, Maxime Legues, Ali Bouamrani, Adrien Mombrun, Benoit Gilquin, Sophie Gerbaud, Patricia Obeid, Fréderique Kermarrec, Xavier Gidrol and Donald K. Martin
appropriately to drugs used to treat prostatecancer ( 2 ) The use of organoids, as 3D culture models would provide even closer tissue-like conditions for studying drug reaction ( 3 ). Those types of 3D cell-culture systems provide information of cell responses that are measurable by imaging or spectroscopic techniques. The limitation of those 3D epithelial models for acinar structures is that it is not possible to access the luminal secretions to measure physiological responses in real-time and to identify new cancer biomarkers.
The use of microfabricated systems, or
Laura Paneghetti, Andrea Gallotta, Chiara Parrozzani and Giorgio Fassina
to satisfy this still unmet medical need.
A novel source of biomarkers derives from the exploitation of the immune-surveillance against transformed malignant cells, since most, if not all, tumours are immunogenic. In many cancer biomarkers may be detected in the patients’ sera as immune complexes. These biomarkers are formed by immunoglobulins-M bound with low affinity and high avidity to markers expressed during cancer ( 4 ). Occurrence of immune complexes has been reported in several cases: prostate specific antigen (PSA)-IgM in prostatecancer( 5
Anthony Singer, Eleni Markoutsa, Alya Limayem, Subhra Mohapatra and Shyam S. Mohapatra
A review of drug delivery systems based on nanotechnology and green chemistry: green nanomedicine Int J Nanomed 2017 12 2957 2978
9 Dilnawaz F, Acharya S, Sahoo SK. Recent trends of nanomedicinal approaches in clinics. Int J Pharm 2018; 538:263-278. 10.1016/j.ijpharm.2018.01.016 29339248
Dilnawaz F Acharya S Sahoo SK Recent trends of nanomedicinal approaches in clinics Int J Pharm 2018 538 263 278
10 Paccez JD, et al. The receptor tyrosine kinase Axl is an essential regulator of prostatecancer proliferation and tumor growth and
8. Vitalone A, Bordi F, Baldazzi C, Mazzanti G, Saso L, Tita B. Antiproliferative effect on a prostatic epithelial cell line (PZ-HPV-7) by Epilobium angustifolium L. Farmaco 2001; 56 (5-7): 483-489.
9. Vitalone A, Guizzetti M, Costa LG, Tita B. Extracts of various species of Epilobium inhibit proliferation of human prostate cells. J Pharm Pharmacol 2003; 55(5): 683-690.
10. Stolarczyk M, Naruszewicz M, Kiss AK. Extracts from Epilobium sp. herbs induce apoptosis in human hormone-dependent prostatecancer cells by activating the
., Gerson R., White E., Rodriguez A., Walter J.C., Livingston D.M. The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly. Cell. 2006, 127:539-552.
53. Gust K. M., Hofer M. D., Perner S.R., Chinnaiyan A. M., VaramballyS., Moller P., Rinnab L., Rubin M. A., Greiner J., Schmitt M., Kuefer R., and Ringhoffer M. RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostatecancer disease. Neoplasia. 2009, 11(9): 956-963.
54. Wang C., Thor A.D., Moore D.H., Zhao Y